Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Michelle Dahdouh

Infectious Disease Bronx, NY Medical Doctor

NPI 1952377558 CMS profile 270379

4422 3Rd Ave, St. Barnabas Hospital Dept. Of Medicine - Rm 714, Bronx, NY 10457

Open in the dashboard

General payments

$1,425

64 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Michelle Dahdouh of Bronx, NY is reported in the CMS Open Payments database as having received $1,425 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $147 7
2023 General $260 13
2022 General $353 15
2020 General $110 6
2019 General $555 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Dahdouh
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Michelle Dahdouh were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Michelle Dahdouh Infectious Disease median Middle half National median
2019 $555 $190 $60–$862 $163
2020 $110 $124 $32–$606 $114
2021 $0 $148 $38–$905 $132
2022 $353 $166 $50–$834 $149
2023 $260 $171 $57–$787 $160
2024 $147 $176 $52–$752 $164
2025 $0 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. ViiV Healthcare Company $451 23 payments
  2. Janssen Biotech, Inc. $272 11 payments
  3. Gilead Sciences, Inc. $131 7 payments
  4. Merck Sharp & Dohme Corporation $110 6 payments
  5. Insmed, Inc. $99 1 payment
  6. Allergan Inc. $86 5 payments
  7. Janssen Products, LP $85 1 payment
  8. Shionogi Inc $48 3 payments
  9. Exact Sciences Corporation $37 2 payments
  10. Janssen Pharmaceuticals, Inc $28 1 payment
  11. Other $78 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,186 59 payments
  2. Education $238 5 payments
Products named General payments · program years 2019–2024
  1. SYMTUZA $294 10 payments
  2. DOVATO $238 12 payments
  3. Arikayce $99 1 payment
  4. PIFELTRO $97 5 payments
  5. DELSTRIGO $97 5 payments
  6. APRETUDE $89 3 payments
  7. AVYCAZ $67 4 payments
  8. RUKOBIA $63 5 payments
  9. PREZCOBIX $63 2 payments
  10. ISENTRESS $50 3 payments
  11. Other $372 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

1,116

Median for Infectious Disease: 268

Drug cost

$1,063,868

Median for Infectious Disease: $217,595

Branded share of claims

40.3%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 94 $416,524
Juluca Dolutegravir/Rilpivirine Brand 37 $147,400
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 20 $89,360
Dalvance Dalbavancin Hcl Brand 18 $86,892
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 15 $70,022
Dovato Dolutegravir Sodium/Lamivudine Brand 19 $54,468
Triumeq Abacavir/Dolutegravir/Lamivudi Brand 12 $44,952
Tivicay Dolutegravir Sodium Brand 17 $40,252
Xifaxan Rifaximin Brand 13 $39,754
Pifeltro Doravirine Brand 20 $33,977

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$11,301

Medicare's payments for the services billed

Medicare patients

65

Average age 68

Services billed

107

17 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 57%
Heart failure 49%
Depression 49%
COPD 48%
Alzheimer's or dementia 38%
Arthritis 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DOVATO
  • ViiV Healthcare Company $82
$82 19 —
Fetroja
  • Shionogi Inc $34
$34 — —
CABENUVA
  • ViiV Healthcare Company $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record